Conferences - Results from #8520

Viewing 8521-8540 of 11775 articles

SUO 2017: Progression-Free Survival (PSA) Endpoint

SUO 2017: Genomic Analysis of Same-Patient Metachronous Upper-Tract and Bladder Urothelial Carcinoma

SUO 2017: Adjuvant Therapies in Kidney Cancer: Critique, Current Trials and Future Directions

SUO 2017: Neoadjuvant Versus Adjuvant Chemotherapy for MIBC: A Propensity Matched Analysis

SUO 2017: Objective Measures of Frailty as Predictors of Postoperative Complications After Radical Cystectomy

SUO 2017: APOBEC-Mediated Mutagenesis in Urothelial Carcinoma - Associated with Improved Survival

SUO 2017: Primary Adrenal Malignancy: Insights Into The Epidemiology Of A Rare Histological Subset

SUO 2017: Flexible Blue Light Cystoscopy with Hexaminolevulinate (HAL) in the Surveillance of Bladder Cancer

SUO 2017: The Probability Of Indolent Versus Aggressive Histology Based On Renal Tumor Size: Implications For Surveillance And Treatment

SUO 2017: A Phase 3 Trial To Compare Efficacy And Safety Of Lenvatinib In Combination With Everolimus Or Pembrolizumab Vs Sunitinib Alone In First-line Treatment Of Patients With Metastatic Renal Cell Carcinoma

SUO 2017: Targeted Therapy Prior To Cytoreductive Nephrectomy For IMDC Intermediate And Poor Risk Patients

SUO 2017: The Urologist's Role in Advanced Renal Cancer

SUO 2017: Utility Of Lymph Node Dissection For Clinical Node Negative Upper Tract Urothelial Cell Carcinoma: A Multicenter Study

SUO 2017: Validation of The BCG Unresponsive Definition

SUO 2017: The Impact of The Affordable Care Act and Medicaid Expansion on Insurance Status and Cancer Staging for Bladder Cancer Patients

SUO 2017: Molecular Profile of Non-Invasive Bladder Cancer

SUO 2017: Promise of Checkpoint Inhibitors for BCG-Unresponsive NMIBC

SUO 2017: Aberrant Histology in NMIBC - What Do We Know and Not Know?

SUO 2017: High Competing Risks Minimize Real-world Utility Of Adjuvant Targeted Therapy In Renal Cell Carcinoma: A Population-based Analysis

SUO 2017: Pathologic Downstaging Following Neoadjuvant Chemotherapy In Patients With High-risk Upper Tract Urothelial Carcinoma

422
423
424
425
426
427
428
429
430
431